Login to Your Account

Clinic Roundup

Wednesday, May 4, 2011
PolyMedix Inc., of Radnor, Pa., presented data from two Phase Ib/II trials of PMX-60056, a synthetic small molecule designed to reverse the anticoagulation activity of heparin and low molecular weight heparins. The data suggested that both heparin and tinzaparin appear to bind on a one-to-one molecular basis with PMX-60056, which could simplify dosing in future trials. The compound is in a Phase II trial to assess the safety and efficacy of reversing heparin in patients undergoing percutaneous coronary intervention procedures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription